JPWO2021028299A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021028299A5 JPWO2021028299A5 JP2022507566A JP2022507566A JPWO2021028299A5 JP WO2021028299 A5 JPWO2021028299 A5 JP WO2021028299A5 JP 2022507566 A JP2022507566 A JP 2022507566A JP 2022507566 A JP2022507566 A JP 2022507566A JP WO2021028299 A5 JPWO2021028299 A5 JP WO2021028299A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- aav
- promoter
- itr
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382706.0 | 2019-08-12 | ||
| EP19382706 | 2019-08-12 | ||
| PCT/EP2020/072087 WO2021028299A1 (en) | 2019-08-12 | 2020-08-06 | Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500011A JP2023500011A (ja) | 2023-01-04 |
| JPWO2021028299A5 true JPWO2021028299A5 (https=) | 2023-08-08 |
| JP2023500011A5 JP2023500011A5 (https=) | 2023-08-08 |
Family
ID=67659024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022507566A Withdrawn JP2023500011A (ja) | 2019-08-12 | 2020-08-06 | 遺伝子療法によるパーキンソン病などのシヌクレイノパチーの治療に使用するためのウイルス粒子 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220298528A1 (https=) |
| EP (1) | EP4013437A1 (https=) |
| JP (1) | JP2023500011A (https=) |
| KR (1) | KR20220099944A (https=) |
| CN (1) | CN114786694A (https=) |
| AR (1) | AR119609A1 (https=) |
| AU (1) | AU2020328827A1 (https=) |
| BR (1) | BR112022002615A2 (https=) |
| CA (1) | CA3149844A1 (https=) |
| CL (1) | CL2022000292A1 (https=) |
| CO (1) | CO2022001192A2 (https=) |
| EC (1) | ECSP22008949A (https=) |
| IL (1) | IL290357A (https=) |
| MX (1) | MX2022001676A (https=) |
| PE (1) | PE20220601A1 (https=) |
| PH (1) | PH12022550282A1 (https=) |
| TW (1) | TW202120687A (https=) |
| WO (1) | WO2021028299A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021015312A2 (pt) | 2019-02-04 | 2021-11-09 | Freeline Therapeutics Ltd | Polinucleotídeos, partícula viral e composição |
| EP4192961A2 (en) * | 2020-08-06 | 2023-06-14 | Fundacion para la Investigacion Medica Aplicada | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy |
| WO2023202637A1 (en) * | 2022-04-19 | 2023-10-26 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant aav vectors for treating neurodegenerative disorders |
| WO2024074142A1 (en) * | 2022-10-08 | 2024-04-11 | Lingyi Biotech Co., Ltd. | Polynucleotides for the treatment of disease associated with gcase deficiency |
| WO2025063407A1 (ko) * | 2023-09-22 | 2025-03-27 | 주식회사 스탠드업테라퓨티스 | 신규한 파킨슨 병 치료제 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3292206B8 (en) * | 2015-05-07 | 2022-02-09 | Takeda Pharmaceutical Company Limited | Glucocerebrosidase gene therapy for parkinson's disease |
| EP3692075A4 (en) * | 2017-10-03 | 2022-02-09 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| WO2019068854A1 (en) * | 2017-10-06 | 2019-04-11 | Ospedale San Raffaele S.R.L. | GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS |
-
2020
- 2020-08-06 WO PCT/EP2020/072087 patent/WO2021028299A1/en not_active Ceased
- 2020-08-06 TW TW109126665A patent/TW202120687A/zh unknown
- 2020-08-06 US US17/634,112 patent/US20220298528A1/en not_active Abandoned
- 2020-08-06 BR BR112022002615A patent/BR112022002615A2/pt not_active IP Right Cessation
- 2020-08-06 AR ARP200102236A patent/AR119609A1/es not_active Application Discontinuation
- 2020-08-06 AU AU2020328827A patent/AU2020328827A1/en not_active Abandoned
- 2020-08-06 CN CN202080064577.2A patent/CN114786694A/zh active Pending
- 2020-08-06 JP JP2022507566A patent/JP2023500011A/ja not_active Withdrawn
- 2020-08-06 CA CA3149844A patent/CA3149844A1/en active Pending
- 2020-08-06 EP EP20750277.4A patent/EP4013437A1/en not_active Withdrawn
- 2020-08-06 KR KR1020227003990A patent/KR20220099944A/ko active Pending
- 2020-08-06 PE PE2022000219A patent/PE20220601A1/es unknown
- 2020-08-06 MX MX2022001676A patent/MX2022001676A/es unknown
- 2020-08-06 PH PH1/2022/550282A patent/PH12022550282A1/en unknown
-
2022
- 2022-02-04 CL CL2022000292A patent/CL2022000292A1/es unknown
- 2022-02-04 CO CONC2022/0001192A patent/CO2022001192A2/es unknown
- 2022-02-04 EC ECSENADI20228949A patent/ECSP22008949A/es unknown
- 2022-02-06 IL IL290357A patent/IL290357A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11738094B2 (en) | Intrathecal delivery of recombinant adeno-associated virus 9 | |
| JP2025179046A5 (https=) | ||
| CN113301956B (zh) | 控制器官功能的基因治疗方法 | |
| TW201629225A (zh) | 第九因子基因療法 | |
| Ciron et al. | Human α-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution | |
| IL300294A (en) | Gene therapy using nucleic acid constructs containing methyl CPG-binding protein 2 (MECP2) promoter sequences | |
| CN119487053A (zh) | 具有优选脑、脊髓和/或心脏表达水平的选定腺相关病毒组合物 | |
| WO2019200286A1 (en) | Bicistronic aav vectors encoding hexosaminidase alpha and beta-subunits and uses thereof | |
| CN121152795A (zh) | 工程化aav衣壳stac-102的适合度成熟 | |
| CN112029773B (zh) | 编码bdnf的核酸及其应用 | |
| JPWO2021028299A5 (https=) | ||
| JP2020510433A5 (https=) | ||
| CN114126667A (zh) | 使用糖苷水解酶的基因疗法载体向视网膜细胞的改进递送 | |
| JPWO2018102665A5 (https=) | ||
| JPWO2022221400A5 (https=) | ||
| JP2023543361A (ja) | Ｎｅｕｒｏｄ１及びｄｌｘ２ベクター | |
| CA3181024A1 (en) | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy | |
| JPWO2022015715A5 (https=) | ||
| RU2022102652A (ru) | Вирусные частицы для применения в лечении синуклеинопатий, таких как болезнь паркинсона, методами генной терапии | |
| US20050143330A1 (en) | Method for the treatment of Parkinson's Disease | |
| TW202317769A (zh) | 來自腺相關病毒血清型９（ａａｖ９）的分離的修飾衣殼蛋白ｖｐ１、基於其的衣殼和載體 | |
| KR20250097939A (ko) | 투여 경로 | |
| EA048714B1 (ru) | Выделенный модифицированный белок vp1 капсида аденоассоциированного вируса 9 серотипа (aav9), капсид и вектор на его основе | |
| Foti | Novel AAV-mediated therapeutic strategies for epilepsy | |
| Deficient | 33. Molecular Characterization of Double-Stranded AAV Vector in Murine Liver |